Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy.

Bone metastases are a significant cause of pain and morbidity in prostate cancer, especially if they lead to complications such as pathological fractures and spinal cord compression. Palliation of pain can be achieved with radiation, radioisotopes, hormone therapy, chemotherapy, and bisphosphonates. Bisphosphonates also reduce the risk of skeletal complications. Studies with animal models and advances in understanding the molecular basis for bone metastases have yielded new targets for therapy. Some of the promising therapeutic trials are reviewed in this paper.

[1]  M. Rogers,et al.  Overview of bisphosphonates , 1997, Cancer.

[2]  S. Rabbani,et al.  Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. , 1994, Cancer research.

[3]  R. Coleman Skeletal complications of malignancy , 1997, Cancer.

[4]  D. Fairclough,et al.  Magnetic resonance imaging of disseminated bone marrow disease in patients treated for malignancy , 2004, Skeletal Radiology.

[5]  C. Tangen,et al.  SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Yarnold,et al.  Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[8]  P. Delmas,et al.  Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. , 1997, Cancer research.

[9]  Mundy,et al.  Bisphosphonates as anticancer drugs. , 1998, Expert opinion on investigational drugs.

[10]  G. Roodman Mechanisms of bone metastasis. , 2004, Discovery medicine.

[11]  L. Collette,et al.  Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. , 2003, European urology.

[12]  A. Zwinderman,et al.  Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. , 1998, Bone.

[13]  L. Matrisian,et al.  Matrix metalloproteinases: multifunctional contributors to tumor progression. , 2000, Molecular medicine today.

[14]  Leonard,et al.  Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. , 1993, Cancer Research.

[15]  M. Chapuy,et al.  Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia , 1983, Cancer.

[16]  L. Chung,et al.  Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[17]  T. Masaki,et al.  The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. , 1990, Biochemical and biophysical research communications.

[18]  F. Orr,et al.  Pathophysiologic interactions in skeletal metastasis , 2000, Cancer.

[19]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[20]  R. Khokha Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. , 1994, Journal of the National Cancer Institute.

[21]  M. Benassi,et al.  The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  Bingham Ja Letter: Lower oesophageal sphincter. , 1974 .

[23]  W. Ashburn,et al.  Nuclear bone imaging in metastatic cancer of the prostate , 1981, Cancer.

[24]  D. Goltzman Mechanisms of the development of osteoblastic metastases , 1997, Cancer.

[25]  Paul J. Williams,et al.  Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. , 2001, Cancer research.

[26]  J. Nelson,et al.  Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Pazdur,et al.  Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  J. Pinski,et al.  Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. , 2001, Cancer research.

[29]  J. Pinski,et al.  Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. , 2002, Cancer research.

[30]  J. Lau,et al.  Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[32]  K. Mohammad,et al.  Role of endothelin‐1 in osteoblastic bone metastases , 2003, Cancer.

[33]  G. Hortobagyi Novel approaches to the management of bone metastases. , 2003, Seminars in oncology.

[34]  T. Suda,et al.  IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. , 1990, Journal of immunology.

[35]  I. Tannock,et al.  Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Kostenuik,et al.  Transforming growth factor β upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen , 2004, Clinical & Experimental Metastasis.

[37]  M. Klagsbrun,et al.  Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. , 1986, The Journal of biological chemistry.

[38]  V. Midy,et al.  Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. , 1994, Biochemical and biophysical research communications.

[39]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[40]  Zuxiong Chen,et al.  Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. , 1996, The Journal of urology.

[41]  C. Contag,et al.  Animal models of bone metastasis , 2003, Cancer.

[42]  S. Magnuson,et al.  Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. , 1996, Cancer research.

[43]  Shelby D Reed,et al.  Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. , 2004, The Journal of urology.

[44]  C. Dinney,et al.  Metastatic model for human prostate cancer using orthotopic implantation in nude mice. , 1992, Journal of the National Cancer Institute.

[45]  C. Sawyers,et al.  Development of an animal model for prostate cancer cell metastasis to adult human bone. , 2001, Anticancer research.

[46]  R. Kryscio,et al.  A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastasis , 2003 .

[47]  E. Ben-Josef,et al.  Systemic bone‐seeking radionuclides for palliation of painful osseous metastases: Current concepts , 1998, CA: a cancer journal for clinicians.

[48]  A. D'Amico,et al.  Prostate cancer : principles and practice , 2002 .

[49]  K. Pienta,et al.  Pain management in patients with advanced prostate cancer. , 1999, Oncology.

[50]  Morris Pollard,et al.  Prostate‐seminal vesicle cancers induced in noble rats , 2000, The Prostate.

[51]  I. Tannock,et al.  A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  G. Mundy Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[53]  M. Robson,et al.  How is androgen-dependent metastatic prostate cancer best treated? , 1996, Hematology/oncology clinics of North America.

[54]  D. Tong,et al.  The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group , 1982, Cancer.

[55]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[56]  A. Geldof,et al.  Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. , 1992, The Journal of urology.

[57]  I. Ikeda,et al.  Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. , 1996, British journal of urology.

[58]  P. Sørensen,et al.  Metastatic epidural spinal cord compression. Results of treatment and survival , 1990, Cancer.

[59]  R. Taichman,et al.  Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein , 2004, Cancer Research.

[60]  D. Rosenthal Radiologic diagnosis of bone metastases , 1997, Cancer.

[61]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[62]  J. Turner,et al.  A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  R. Payne,et al.  Mechanisms and management of bone pain , 1997, Cancer.

[64]  G. Sledge,et al.  Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. , 1995, Journal of the National Cancer Institute.

[65]  G. Oremek,et al.  Diagnostic value of bone and tumour markers in patients with malignant diseases. , 2003, Anticancer research.

[66]  W. Shipley,et al.  Management of spinal cord compression secondary to metastatic prostatic carcinoma. , 1991, The Urologic clinics of North America.

[67]  L. Collette,et al.  Strontium89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group , 2003 .

[68]  M. Kattan,et al.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. , 2001, Urology.